Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
暂无分享,去创建一个
G. Massonnet | P. Rousselot | E. Verhoeyen | C. Chomienne | J. Beressi | P. Leboulch | S. Chrétien | Joseph Saliba | Francis Relouzat | M. Spentchian | S. Castaigne | S. Prost | B. Manéglier | Victoria Raggueneau | Yasmine Ouzegdouh | Francis Relouzat
[1] J. Qi,et al. Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 , 2014, Molecular Cancer Therapeutics.
[2] Yu-Chung Yang,et al. Cited2 in hematopoietic stem cell function , 2013, Current opinion in hematology.
[3] J. Cayuela,et al. Targeting STAT5 Expression Resulted in Molecular Response Improvement in Patients with Chronic Phase CML Treated with Imatinib , 2012 .
[4] R. Clark,et al. Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. , 2012, Experimental hematology.
[5] P. Pandolfi,et al. A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance , 2012, Nature Medicine.
[6] S. Dunwoodie,et al. HIF-1α deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency. , 2012, Blood.
[7] R. Bhatia,et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. , 2012, Blood.
[8] Peter Dirks,et al. Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.
[9] F. Aguilo,et al. Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-β2 and FLT3 in hematopoiesis. , 2011, Blood.
[10] A. Turhan,et al. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy , 2011, Oncotarget.
[11] E. Vellenga,et al. Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. , 2011, Blood.
[12] B. Druker,et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.
[13] S. Koschmieder,et al. Mouse models as tools to understand and study BCR-ABL1 diseases. , 2011, American journal of blood research.
[14] D. Carson,et al. Repression of beta-catenin signaling by PPAR gamma ligands. , 2010, European journal of pharmacology.
[15] L. Hennighausen,et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia , 2010, EMBO molecular medicine.
[16] P. Devillier,et al. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[17] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[18] C. Peng,et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia , 2009, Nature Genetics.
[19] M. Koutsilieris,et al. IL-6 and PPARγ Signalling in Human PC-3 Prostate Cancer Cells , 2009 .
[20] J. Klawitter,et al. Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells , 2009, Clinical Cancer Research.
[21] W. Tse,et al. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement , 2009 .
[22] T. Harkness,et al. Troglitazone reverses the multiple drug resistance phenotype in cancer cells , 2009, Drug design, development and therapy.
[23] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[24] Jaspal Kaeda,et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] N. Déglon,et al. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARgamma/STAT5 signaling pathway in macaques. , 2008, The Journal of clinical investigation.
[26] M. Simon,et al. The N-Terminal Transactivation Domain Confers Target Gene Specificity of Hypoxia-inducible Factors HIF-1α and HIF-2α , 2007 .
[27] Yu-Chung Yang,et al. Cited2 is required for normal hematopoiesis in the murine fetal liver. , 2007, Blood.
[28] Y. Miyazaki,et al. Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus , 2007, Clinical pharmacology and therapeutics.
[29] T. Holyoake,et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. , 2007, Blood.
[30] M. Copland,et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.
[31] A. Szántó,et al. Retinoids Potentiate Peroxisome Proliferator-Activated Receptor γ Action in Differentiation, Gene Expression, and Lipid Metabolic Processes in Developing Myeloid Cells , 2005, Molecular Pharmacology.
[32] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[33] T. Holyoake,et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.
[34] P. Vidalain,et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells , 2000, Gene Therapy.
[35] J. Marine,et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. , 2000, Genes & development.
[36] A. Yoshimura,et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. , 1997, Blood.